Literature DB >> 29067605

Surgical Management of Primary Retroperitoneal Sarcomas: Rationale for Selective Organ Resection.

Mark Fairweather1,2, Jiping Wang1,2,3, Vickie Y Jo2,3,4, Elizabeth H Baldini2,3,5, Monica M Bertagnolli1,2,3, Chandrajit P Raut6,7,8.   

Abstract

BACKGROUND: Recently, some have argued for routine resection of adjacent but uninvolved organs in patients with retroperitoneal sarcoma (RPS) without stipulating the rationale for such organ resection (beyond the need to achieve a macroscopically complete resection) or examining histopathologic organ invasion (HOI). This study reviewed the authors' experience with primary RPS to investigate the rate and rationale for individual organ resection and the rate of HOI.
METHODS: Operative and pathology reports for patients with primary RPS who underwent resection at our institution were retrospectively reviewed. Histopathologic organ invasion was confirmed by a dedicated sarcoma pathologist.
RESULTS: From 2002 through 2011, 118 patients underwent resection of a primary RPS, and 99 of these patients (84%) had at least one organ resected. Kidney (n = 57), colon (n = 51), and adrenal (n = 41) were the most commonly resected organs. For the 302 organs removed, the perioperative clinical rationale for the resection was suspected invasion or tumor origin (n = 52, 17%), involved end-organ vasculature (n = 39, 13%), organ encasement (n = 42, 14%), tumor adherence (n = 127, 42%), resection required for R0/R1 resection (n = 25, 8%), or other (n = 17, 6%). The presence of HOI was found in 77 (25%) of the 302 organs resected. In the reviewed studies, HOI was identified in 34 (65%) of 52 organs suspected of invasion or tumor origin, in 19% of organs resected due to tumor encasement, and in 26% of organs with adherent tumor, even when not suspected intraoperatively, but was never identified in organs resected purely as part of a liberal en bloc resection of adjacent organs. When invasion was suspected intraoperatively, HOI was confirmed in 50, 78, and 100% of resected organs respectively for well-dedifferentiated liposarcoma, dedifferentiated liposarcoma (DDLPS), and leiomyosarcoma (LMS).
CONCLUSIONS: Histologic organ invasion was observed more commonly in organs resected with suspicion of invasion than in organs resected simply to achieve a negative margin, although this reflects a degree of subjectivity and selection bias. In more than one-fourth of adherent organs, HOI was present even when not suspected intraoperatively. Histologic subtype may predict HOI because DDLPS and LMS are associated with high rates of HOI when invasion is suspected intraoperatively. Development of a data-driven, histology-specific rationale for adjacent organ resection is critical.

Entities:  

Mesh:

Year:  2017        PMID: 29067605     DOI: 10.1245/s10434-017-6136-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma.

Authors:  Emily Z Keung; Yi-Ju Chiang; Janice N Cormier; Keila E Torres; Kelly K Hunt; Barry W Feig; Christina L Roland
Journal:  Cancer       Date:  2018-10-14       Impact factor: 6.860

Review 2.  [Retroperitoneal soft tissue sarcoma: surgical management].

Authors:  Franziska Willis; Martin Schneider
Journal:  Chirurg       Date:  2021-10-01       Impact factor: 0.955

3.  National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma: A Modern Appraisal of Variability in Therapeutic Strategies.

Authors:  Anthony M Villano; Roberto J Vidri; Elaine T Vo; Stephanie H Greco; Krisha J Howell; Margaret von Mehren; Jeffrey M Farma
Journal:  Ann Surg Oncol       Date:  2021-10-11       Impact factor: 5.344

Review 4.  Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma.

Authors:  Megan Delisle; David Gyorki; Sylvie Bonvalot; Carolyn Nessim
Journal:  Ann Surg Oncol       Date:  2022-09-10       Impact factor: 4.339

5.  Case Report: Retroperitoneal Sarcoma in Six Operations: Our Experience in Operative Management of Blood Vessels.

Authors:  Jinhui Guo; Fabo Qiu; Jie Zhao; Qiliang Lu; Wen Fu; Qiuran Xu; Dongsheng Huang
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

Review 6.  Immunohistochemical Biomarkers of Mesenchymal Neoplasms in Endocrine Organs: Diagnostic Pitfalls and Recent Discoveries.

Authors:  Yin P Hung; Jason L Hornick
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

7.  Predictive Value of Preoperative Controlling Nutritional Status Score Combined with Fibrinogen-Albumin Ratio in Postoperative Local Recurrence-Free Survival of Patients with Retroperitoneal Liposarcoma.

Authors:  Guo-Qiang Xue; Cheng-Peng Li; Ang Lv; Xiu-Yun Tian; Jian-Hui Wu; Hui Qiu; Chun-Yi Hao
Journal:  Cancer Manag Res       Date:  2021-08-06       Impact factor: 3.989

8.  Prognostic implications of histological organ involvement in retroperitoneal sarcoma.

Authors:  R Tyler; M Lee; V Ierodiakonou; J Hodson; P Taniere; M Almond; S Ford; A Desai
Journal:  BJS Open       Date:  2021-09-06

Review 9.  Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas-Looking Forward.

Authors:  Alexandra C Istl; Alessandro Gronchi
Journal:  Cancers (Basel)       Date:  2022-04-05       Impact factor: 6.639

10.  Radical Versus Non-Radical Resection for Early-Stage Retroperitoneal Sarcoma: A Propensity Score-Matched Analysis.

Authors:  Chengxin Weng; Jiarong Wang; Jichun Zhao; Ding Yuan; Bin Huang; Tiehao Wang
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.